Kunena :: Тема: Posted by Ilene on 29.11.2016 8:13:54: erlotinib rash and efficacy (1/2)

Навигация: Главная Форум Главный раздел Сообщество базовых площадокPosted by Ilene on 29.11.2016 8:13:54: erlotinib rash and efficacy

Добро пожаловать, Гость

Форум

Главный раздел

Сообщество базовых площадок

Posted by Ilene on 29.11.2016 8:13:54: erlotinib rash and efficacy

Страница:
1
2

ТЕМА: Posted by Ilene on 29.11.2016 8:13:54: erlotinib rash and efficacy

Posted by Ilene on 29.11.2016 8:13:54: erlotinib rash and efficacy 7 года 5 мес. назад #907

akipk

High Quality - Low Cost Anti-Cancer Drugs

*
Drug: Tarceva Drug: Temodar Procedure: Radiation Therapy
Gopakumar Nair, another patent consultant, had a different view. “Erlotinib is a derivative of another known cancer drug gefitinib, a pre-1995 invention of European drug maker AstraZeneca. Since (the) Delhi patent office had denied a patent for this (the AstraZeneca) drug, a patent for its derivative will not be strong, and the generic company can get the patent revoked through a post-grant opposition,” Nair said.
www.ladies-news.ru/index.php/forum/obsuz...-gefitinib-erlotinib
Bottom line is, even without the mutation, Tarceva still should be considered as a viable part of the arsenal against NSCLC. I'm glad our oncologist was willing to give it a try, even though there was no response. I hope that future health care plans won't require the EGFR mutation be present in order for a patient to try Tarceva, when it clearly shows a significant enough benefit.
Comment: In 2013 I was diagnosed with NSCLC in right upper lobe. Cancer was discoveredp in 2 stages of the lymp nodes. Had 25 treatments of radiation and 5 treatments of chemo. Neither treatments showed shrinkage but tumor did not grow. Had surgery of removal of right upper lobe after treatments. Had CT scan 3 months after surgery and found many small spots of cancer cells in both lungs. Started 150 mg of Tarceva. Had 2 CT since I started Tarceva with great improvement. It is so important to have a positive attitude, stay strong and eat healthy. I go to the YMCA 3 times a week and walk almost every day. Yoga has been a terrific help with improving my breathing and a mind and body balance. I do get a rash on my face when sitting in the sun or when I eat or drink certain foods. Eyelash get very long and need trimming to avoid dragging against the eyeglass lenses. Facial peach fuzz hair gone but do have some dark hair pop up. I found taking Tarceva in the morning on an empty stomach works best. I was devastated in knowing, as most people are, that I had lung cancer but after seeing so many young people with similar and worse cancer issue I got out of my pity pity me and decided to enjoy ever day that I am given. Stay strong for you are not alone in fighting this terrible disease. Hide Full Comment
a third study compared Tarceva with placebo in 643 patients with advanced NSCLC whose cancer cells did not have EGFR activating mutations and whose disease was stable after initial treatment with four cycles of platinum-containing chemotherapy. The study compared how long patients survived when Tarceva was used early in the study with how long they survived when Tarceva was used later in the study.
In den USA werden Herceptin, MabThera (Rituxan), Avastin und Tarceva entweder exklusiv von Genentech vermarktet oder zusammen mit den Partnerunternehmen Biogen Idec Inc. (MabThera) oder OSI (Tarceva). Ausserhalb der USA sind Roche und die japanische Partnerfirma Chugai für den Vertrieb von diesen Medikamenten verantwortlich.
Se han observado casos poco frecuentes de reacciones semejantes a enfermedad pulmonar intersticial. incluyendo fallecimientos, en pacientes que fueron tratados con erlotinib para el cáncer de pulmón no microcítico, cáncer de páncreas u otros tumores sólidos avanzados. En el cancer de pulmón, la incidencia de enfermedad pulmonar intersticial fue del 0.8% igual que el placebo. Sin embargo, en el cáncer de pancreas concomitantemente con gemcitabina, la incidencia de enfermedad pulmonar intersticial fué del 2.5% para la combinación frente al 0.4% en los pacientes tratados con gemcitabina en monoterapia. Globalmente, se estima un incidencia del 0.6% en los pacientes tratados con erlotinib frente al 0.2% en los tratados con placebo o con quimioterapia concurrente. Los diagnósticos en los que se sospechó una enfermedad pulmonar intersticial fueron neumonitis, neumonitis causada por radiación, neumonitis por hipersensibilidad, neumonía intersticial, enfermedad pulmonar intersticial, bronquiolitis obliterante, fibrosis pulmonar, síndrome de distrés respiratorio agudo alveolitis e infiltración pulmonar. Los síntomas se presenta en un intervalo que oscila entre unos pocos días después de iniciado el tratamiento hasta varios meses despues.
Contra-indicações de Tarceva
shkolyar-chg.ru/index.php/forum/razdel-p...0-buy-tarceva-150-mg
Applying for Tarceva Patient Assistance doesn't have to be a daunting task
The serum concentration of Erlotinib can be decreased when it is combined with Famotidine.
Tarceva – the wonder drug that wasn’t
steptoperfection.ru/index.php/en/forum/r...a-patient-assistance
The NCIC CTG PA.3 trial was an international study that randomized patients with advanced pancreatic cancer to receive either gemcitabine in combination with erlotinib or placebo as first-line treatment. The primary endpoint was OS, and the secondary endpoints were PFS, response rate (RR), response duration, toxicity, and quality of life.
Vivek K. Mehta, R adiotherapy and erlotinibcombined:review of the preclinical and clinical evidence REVIEW ARTICLE published: 10April2012
Overall survival was not superior in patients randomized to receive maintenance TARCEVA followed by chemotherapy upon progression compared to patients randomized to receive maintenance placebo followed by TARCEVA upon progression (HR=1.02, 95% CI, 0.85 to 1.22, p=0.82). In the maintenance phase, patients who received TARCEVA did not have superior progression-free survival compared with patients who received placebo (HR=0.94, 95% CI, 0.80 to 1.11, p =0.48).
Keywords: nonsmall cell lung cancer, erlotinib, cost-benefit analysis, epidermal growth factor receptor, wild-type, Europe
school65.zp.ua/index.php/kunena/informat...-12-11-xgeva-tarceva
MAINTENANCE THERAPY: Patients achieving complete response, partial response, or stable disease after completion of induction therapy will receive bevacizumab IV over 30-90 minutes once every 14 or 21 days and erlotinib hydrochloride orally (PO) once daily (QD) in the absence of disease progression or unacceptable toxicity.
In conclusion, the combination of sorafenib and erlotinib does not have promising clinical activity in an unselected population of patients with biliary cancers. Improved patient selection based on tumour location, tumour biology and molecular markers will be critical for future evaluation of targeted therapies in this heterogenous disease.
The parental HEK293-pcDNA3.1 and HEK-MRP7-2 transfected cells were seeded in two T75 flasks and incubated with DMEM supplemented with 10% bovine serum at 37°C. After the cells reached 90% confluency, the cells were trypsinized and two aliquots (48 × 10 6 cells) from each cell line were suspended in the medium, pre-incubated with or without lapatinib/erlotinib (2.5 μM) at 37°C for 1 h. Subsequently, cells were suspended in the medium containing 0.1 μM [ 3 H]-paclitaxel with or without lapatinib/erlotinib at 37°C for 1 h. The cells were washed with PBS for three times, and then suspended in fresh medium with or without lapatinib/erlotinib at 37°C. Aliquots (1 × 10 6 cells) were collected at various time points (0, 30, 60, 120 min), followed by placed in scintillation fluid to measure the radioactivity by a Packard TRI-CARB 1900CA liquid scintillation counter (Packard Instrument Inc. Downers Grove, IL).
www.facecool.com/profiles/blogs/posted-b...9-05-what-if-tarceva
Im Hinblick auf die Toxizitäten zeigten sich deutliche Vorteile für Erlotinib. Erwartungsgemäss waren zwar Rash und Diarrhö häufiger im Erlotinib-Arm. Jedoch waren diese überwiegend leicht bis moderat ausgeprägt (Grad 1/2). Erlotinib zeigte keine hämatologischen Nebenwirkungen wie febrile Neutropenie oder Anämien. Diese waren unter der Second-Line-Therapie mit der Chemotherapie dagegen ausgeprägt. Im Chemotherapie-Arm hatten mehr Patienten schwerwiegende Nebenwirkungen (Chemotherapie: 14,6% vs. Erlotinib: 10,2%), therapiebedingte schwerwiegende Nebenwirkungen (Chemotherapie: 6,6% vs. Erlotinib: 1,0%) sowie Nebenwirkungen mit Todesfolge (Chemotherapie: 5,2% vs. Erlotinib: 1,5%).
In the standard arm, 371 patients received at least one cycle of cisplatin-gemcitabine chemotherapy with 5 being the median number of cycles received. Documented disease progression was confirmed in 316 patients of whom 28.5% did not receive second-line erlotinib. In the experimental arm, 373 patients received at least one dose of erlotinib, disease progression was documented in 333 patients and 41.7% of these patients did not receive second-line therapy. After 24.3 months median follow up, patients treated in the standard arm had longer first-PFS, PFS and OS ( Table 1 ). EGFR wild type patients enrolled in the standard arm had longer PFS and OS whilst patients with EGFR mutations treated in the experimental arm had longer first-PFS but shorter PFS and OS ( Table 2 ). It is important to point out that this is based on a maximum of 38 events in the two arms.
Lebih dari 182,000 pasien di seluruh dunia telah dirawat menggunakan Tarceva sejak diluncurkan tiga tahun yang lalu. Data terkini ini memperkuat bahwa Tarceva menetapi janjinya dalam menawarkan keberlangsungan hidup lebih lama dan kualitas hidup yang lebih baik pada jajaran luas dari sejumlah pasien, pria, wanita, perokok, bukan perokok dan orang-orang dari jajaran luas beberapa kelompok etnik-dengan NSCLC, salah satu bentuk kanker paling mematikan di dunia.
100 mg/d erlotinib and placebo
The serum concentration of Erlotinib can be increased when it is combined with Loperamide.
No data are currently available regarding the influence of hepatic dysfunction and/or hepatic metastases on the pharmacokinetics of erlotinib. As in vitro and in vivo evidence suggest that erlotinib is cleared primarily by the liver, caution should be used when giving erlotinib to patients with hepatic impairment. Dose reduction or interruption of erlotinib should be considered should severe adverse reactions occur.
Cross-over response to erlotinib of brain metastatic disease from bronchial adenocarcinoma after gefitinib failure, and an unusual rash
os-sport.ru/forum/раздел-предложений/139...in-south-africa#1397
erlotinib oral will increase the level or effect of metronidazole oral by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
Patient Ratings for Tarceva
Dear Dr. West, How are you doing? Happy New Year 2015. Thanks so much for your kind, faithful and excellent service for the lung cancer patients and families! I have not posted here for almost a year now, which means the <50 mg/day dosage of Tarceva my wife is taking was working fine for her stage 4a NSCLC until now —- however, we just came back from MDA and found that there are some 3-4 nodules in both of her lungs grew slightly in the past 6 months, and the largest one grew to the range of 5 mm (i.e. 0.5 cm). There is no new nodules though. Our oncologist used the wording that she is “disconcerned” at this point, but ask my wife to increase her Tarceva dosage to as much as she can tolerate. My wife has been taking
Volunteers in the Phase I study, patients with advanced lung cancer that had failed to respond to all conventional therapies, took several Celebrex pills and one Tarceva pill each day. After eight weeks, researchers looked at response rates. Patients were able to stay on the study as long as they didn't experience tumor growth. The longest duration of response was 93 weeks, Reckamp said, about three to four times longer than the average duration of response for a patient with advanced lung cancer.
One Tarcevan, contrary to “manufacturer’s directions”, has found Clindamycin effective for pustules in her nose. She applies it on a Q-tip and finds that the pustules clear up in a few days.
TARCEVA está contraindicado en pacientes con fuerte hipersensibilidad al erlotinib o a cualquier otro componente de TARCEVA.
bowlangarsk.ru/forum/otchety-i-obsuzhden...eva-roche-prospektüs
Cell proliferation was assessed by using the CellTiter 96 AQueous One Solution Cell Proliferation Assay (Promega, Madison, WI), according to the manufacterer’s instructions. Cells were plated in 96-well plates at 4,000 cells per well. PDLL-coated plates were used for VS and noncoated plates were used for HMS-97 cells. After 24 hours, cells were treated with various concentrations of Erlotinib or Lapatinib with DMSO as a vehicle control at 37°C for 72 hours. After treatment, 20 μL of the MTS assay reagent was added to each well and incubated for 1–3 hours. Since only viable cells will induce a color change, the amount of bio-reduced formazan was estimated by measuring the absorbance at 490 nm. Each treatment condition had six replicates and each experiment was repeated using subsequent cell passages. The untreated wells represented the baseline of viable cells and designated as 100%. The percentage of viable cells for each drug treatment compared with the untreated wells was plotted against the concentration of drug. The mean percentage with standard deviations were calculated. These data were used for qualitative and descriptive purposes and no further statistical analyses were performed between individual tumors or different inhibitors. The IC 50 value, defined as the drug concentration at which the mean of viable cells decreased to 50%.
Crystalline forms of Erlotinib HCI and formulations thereof
Erlotinib and Chemotherapy for 2nd Line Treatment (Tx) of Metastatic Colorectal Cancer (mCRC)
Erlotinib hydrochloride Property
Univariate analysis shows that longer OS is significantly associated with stage IIIB ( P =0.003) but not with age ( P =0.592), sex ( P =0.416), PS score ( P =0.603), erlotinib/chemotherapy administration ( P =0.924), EGFR mutation genotypes ( P =0.937), or first-/second-line treatment ( P =0.604). In multivariate analysis, OS remained longer for patients with stage IIIB disease (HR, 1.719; 95% CI, 1.192–2.479; P =0.004).
Tiseo M, Gridelli C, Cascinu S, Crino L, Piantedosi FV, Grossi F, Brandes AA, Labianca R, Siena S, Amoroso D, Belvedere O, Valentino B, Bearz A, Venturino P, Ardizzoni A (2009) An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): data report from Italy. Lung Cancer 64. 199–206 | Article | PubMed |